Pesquisas alternativas:
doses develop » loss develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa), locus develop (Expandir a Pesquisa)
develop them » develop type (Expandir a Pesquisa)
does develop » boys develop (Expandir a Pesquisa), loss develop (Expandir a Pesquisa), does developing (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
drug does » drugs does (Expandir a Pesquisa), drug dose (Expandir a Pesquisa), drug de (Expandir a Pesquisa)
doses develop » loss develop (Expandir a Pesquisa), models develop (Expandir a Pesquisa), locus develop (Expandir a Pesquisa)
develop them » develop type (Expandir a Pesquisa)
does develop » boys develop (Expandir a Pesquisa), loss develop (Expandir a Pesquisa), does developing (Expandir a Pesquisa)
drug doses » drug dose (Expandir a Pesquisa), drug disease (Expandir a Pesquisa)
drug does » drugs does (Expandir a Pesquisa), drug dose (Expandir a Pesquisa), drug de (Expandir a Pesquisa)
1
Por Yu. M. Gomon, A. A. Kurylev, A. S. Kolbin, M. A. Proskurin, I. G. Ivanov, S. V. Sidorenko, M. A. Arepieva, A. V. Sokolov
Publicado em 2018-10-01
Assuntos:
“...antimicrobial drugs...”Publicado em 2018-10-01
Obter o texto integral
Artigo
2
Por Coppola, Giangennaro, Iapadre, Giulia, Operto, Francesca Felicia, Verrotti, Alberto
Publicado no Drug Des Devel Ther (2017)
“... stages of development. Several of them are already available or in ongoing clinical trials. These new...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
“... products (e.g., drugs) but preclude them from others (e.g., food additives). When not precluded...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Manning, Simon M., Boll, Griffin, Fitzgerald, Erin, Selip, Debra B., Volpe, Joseph J., Jensen, Frances E.
Publicado em 2011
“... brain, we demonstrate here that, in contrast to MK-801, memantine at neuroprotective doses does...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
6
7
Por Compadre, Cesar M., Singh, Awantika, Thakkar, Shraddha, Zheng, Guangrong, Breen, Philip J., Ghosh, Sanchita, Kiaei, Mahmoud, Boerma, Marjan, Varughese, Kottayil I., Hauer-Jensen, Martin
Publicado em 2013
“... for ATTP than does AT, and thus have a longer residence time in the liver, putting them at higher risk...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Payne, Jason N., Waghwani, Hitesh K., Connor, Michael G., Hamilton, William, Tockstein, Sarah, Moolani, Harsh, Chavda, Fenil, Badwaik, Vivek, Lawrenz, Matthew B., Dakshinamurthy, Rajalingam
Publicado no Front Microbiol (2016)
“..., there is a huge demand to develop a new generation of antibiotic agents to fight them. As an alternative...”Publicado no Front Microbiol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Moreira, Wilfried, Lim, Jia Jie, Yeo, Si Ying, Ramanujulu, Pondy M., Dymock, Brian W., Dick, Thomas
Publicado no Front Microbiol (2016)
“... to determine whether any of them can be moved forward as a new antimycobacterial fragment drug candidate....”Publicado no Front Microbiol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Oetjens, Matthew, Bush, William S., Birdwell, Kelly A., Dilks, Holli H., Bowton, Erica A., Denny, Joshua C., Wilke, Russell A., Roden, Dan M., Crawford, Dana C.
Publicado em 2014
“... toxicity from overdosing, but drug monitoring does not alleviate long-term side effects. Patients...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Artigo
11
Por Corcos, Daniel
Publicado em 2013
“... them from high-dose antimitotic chemotherapy, preventing myelosuppression. In its simplest form, cell...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por N. A. Morina, O. D. Savkova, E. A. Fedorova, I. L. Tsarev, A. B. Frolkova, A. E. Tsygankova, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
Publicado em 2017-11-01
“... with hypertension of low/medium risk of development of cardiovascular complications (CVC) and death from them a...”Publicado em 2017-11-01
Obter o texto integral
Artigo
13
“... areas of the posterior pole and the fovea. A method, laser targeted delivery, has been developed capable...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
“... data on safety, dosing, and the choice of anti-VEGF drug are still lacking. CONCLUSION: The available...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Abhilash, B., Tripathi, Chakra Dhar, Gogia, Anoop Raj, Meshram, Girish Gulab, Kumar, Manu, Suraj, B.
Publicado no Indian J Crit Care Med (2015)
“... and the nongastrointestinal groups was significant at 2 h (P = 0.015) following drug dosing; while the difference...”Publicado no Indian J Crit Care Med (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por King, Shelby M., Higgins, J. William, Nino, Celina R., Smith, Timothy R., Paffenroth, Elizabeth H., Fairbairn, Casey E., Docuyanan, Abigail, Shah, Vishal D., Chen, Alice E., Presnell, Sharon C., Nguyen, Deborah G.
Publicado no Front Physiol (2017)
“... site of nephrotoxicity and resulting attrition in the drug development pipeline. Current pre-clinical...”Publicado no Front Physiol (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Zinzi, Laura, Capparelli, Elena, Cantore, Mariangela, Contino, Marialessandra, Leopoldo, Marcello, Colabufo, Nicola Antonio
Publicado em 2014
“... ligands have been developed and, among them, Tariquidar has been extensively studied both in vitro...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Hait, N C, Avni, D, Yamada, A, Nagahashi, M, Aoyagi, T, Aoki, H, Dumur, C I, Zelenko, Z, Gallagher, E J, Leroith, D, Milstien, S, Takabe, K, Spiegel, S
Publicado no Oncogenesis (2015)
“... mice. Oral administration of clinically relevant doses of FTY720 suppressed development, progression...”Publicado no Oncogenesis (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
“... into the urine, specific assays were developed for this matrix to determine them quantitatively of qualitatively...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Publicado em 2004
“... intraoperative awareness and help to ensure that an exact dose of anaesthetic drugs is given to minimize adverse...”Obter o texto integral
Obter o texto integral
Artigo